Mechanistic Model‐Informed Proarrhythmic Risk Assessment of Drugs: Review of the “CiPA” Initiative and Design of a Prospective Clinical Validation Study
Open Access
- 7 October 2017
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 103 (1) , 54-66
Abstract
The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative is developing and validating a mechanistic‐based assessment of the proarrhythmic risk of drugs. CiPA proposes to assess a drug's effect on multiple ion channels and integrate the effects in a computer model of the human cardiomyocyte to predict proarrhythmic risk. Unanticipated or missed effects will be assessed with human stem cell‐derived cardiomyocytes and electrocardiogram (ECG) analysis in early phase I clinical trials. This article provides an overview of CiPA and the rationale and design of the CiPA phase I ECG validation clinical trial, which involves assessing an additional ECG biomarker (J‐Tpeak) for QT prolonging drugs. If successful, CiPA will 1) create a pathway for drugs with hERG block / QT prolongation to advance without intensive ECG monitoring in phase III trials if they have low proarrhythmic risk; and 2) enable updating drug labels to be more informative about proarrhythmic risk, not just QT prolongation.Keywords
Funding Information
- FDA Safety Research Interest Group
- Critical Path Initiative in the Center for Drug Evaluation and Research
- FDA's Office of Women's Health
This publication has 53 references indexed in Scilit:
- Simulation of the Undiseased Human Cardiac Ventricular Action Potential: Model Formulation and Experimental ValidationPLOS Computational Biology, 2011
- Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidineHeart Rhythm, 2008
- Augmentation of late sodium current unmasks the proarrhythmic effects of amiodaroneCardiovascular Research, 2007
- L‐Type Calcium Current Reactivation Contributes to Arrhythmogenesis Associated with Action Potential TriangulationJournal of Cardiovascular Electrophysiology, 2007
- Drug-Induced Prolongation of the QT IntervalNew England Journal of Medicine, 2004
- Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointesJACC, 1995
- Cellular Mechanisms of Early AfterdepolarizationsaAnnals of the New York Academy of Sciences, 1992
- Low dose quinidine-mexiletine combination therapy versus quinidine monotherapy for treatment of ventricular arrhythmiasJACC, 1990
- Mexiletine-quinidine combination: Electrophysiologic correlates of a favorable antiarrhythmic interaction in humansJACC, 1987
- Mexiletine in the treatment of resistant ventricular arrhythmias: enhancement of efficacy and reduction of dose-related side effects by combination with quinidine.Circulation, 1983